MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

Search

Johnson and Johnson

Slēgts

SektorsVeselības aprūpe

154.9 -0.37

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

153.41

Max

155.48

Galvenie mērījumi

By Trading Economics

Ienākumi

3.4B

Pārdošana

20M

23B

P/E

Sektora vidējais

17.455

57.333

EPS

2.77

Dividenžu ienesīgums

3.3

Peļņas marža

15.235

Darbinieki

138,100

EBITDA

652M

5.9B

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt

Prognoze 12 mēnešiem

+8.86% upside

Dividendes

By Dow Jones

Dividenžu ienesīgums

Sektora vidējais

3.30%

2.63%

Nākamie ieņēmumi

2025. g. 16. jūl.

Nākamais dividenžu datums

2025. g. 10. jūn.

Nākamais Ex dividenžu datums

2025. g. 27. maijs

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

11B

378B

Iepriekšējā atvēršanas cena

155.27

Iepriekšējā slēgšanas cena

154.9

Tehniskais rādītājs

By Trading Central

Pārliecība

Strong Bullish Evidence

Johnson and Johnson Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 15. apr. 15:12 UTC

Peļņas

J&J Boosts Outlook Despite Incoming Tariff Costs -- Update

2025. g. 15. apr. 10:35 UTC

Top Ziņas
Peļņas

J&J Increases Outlook After Beating 1Q Expectations

2025. g. 18. apr. 11:00 UTC

Top Ziņas

Johnson & Johnson Pivots Its AI Strategy -- WSJ

2025. g. 17. apr. 20:34 UTC

Peļņas

UnitedHealth Woes Aren't Dragging Down the Entire Sector. Here's Why. -- Barrons.com

2025. g. 17. apr. 18:24 UTC

Peļņas

UnitedHealth Woes Aren't Dragging Down the Entire Sector. Here's Why. -- Barrons.com

2025. g. 15. apr. 19:06 UTC

Peļņas

These Stocks Are Moving the Most Today: Bank of America, Citigroup, Netflix, Boeing, Tesla, HPE, Applied Digital, and More -- Barrons.com

2025. g. 15. apr. 18:52 UTC

Tirgus saruna
Peļņas

J&J's 1Q Performance Signals Positive Outlook for MedTech Sector -- Market Talk

2025. g. 15. apr. 14:54 UTC

Peļņas

Why Johnson & Johnson Stock Is Down After Earnings Beat Expectations -- Barrons.com

2025. g. 15. apr. 13:19 UTC

Peļņas
Iegādes, apvienošanās, pārņemšana

Why Johnson & Johnson Stock Is Down After Earnings Beat Expectations -- Barrons.com

2025. g. 15. apr. 11:52 UTC

Peļņas

Johnson & Johnson Tops Earnings Estimates and Boosts Outlook. The Stock Slips. -- Barrons.com

2025. g. 15. apr. 11:14 UTC

Peļņas

Johnson & Johnson Tops Earnings Estimates and Boosts Outlook. The Stock Slips. -- Barrons.com

2025. g. 15. apr. 10:51 UTC

Peļņas

These Stocks Are Moving the Most Today: Boeing, Tesla, Bank of America, J&J, Netflix, Allegro MicroSystems, and More -- Barrons.com

2025. g. 15. apr. 10:37 UTC

Top Ziņas
Peļņas

Johnson & Johnson Tops Earnings Estimates and Boosts Outlook. The Stock Rises. -- Barrons.com

2025. g. 15. apr. 10:20 UTC

Peļņas

Johnson & Johnson Now Sees 2025 Operational Sales of $91.6B-$92.4B Vs. Prior Outlook $90.9B-$91.7B >JNJ

2025. g. 15. apr. 10:20 UTC

Peļņas

Johnson & Johnson Backs 2025 Adj EPS $10.50-Adj EPS $10.70 >JNJ

2025. g. 15. apr. 10:20 UTC

Peļņas

Johnson & Johnson Raises 2025 View To Sales $91B-$91.8B Vs Prior View $89.2B-$90B >JNJ

2025. g. 15. apr. 10:20 UTC

Peļņas

Johnson & Johnson Now Sees 2025 Adjusted Operational EPS $10.50-$10.70 Vs Prior View $10.75-$10.95 >JNJ

2025. g. 15. apr. 10:20 UTC

Peļņas

Johnson & Johnson: Including Tariff Costs, Dilution From Intra-Cellular Therapies Buy and Updated Forex, Maintain FY Adj EPS Outlook of 6.2% Growth at Mid-Point >JNJ

2025. g. 15. apr. 10:20 UTC

Peļņas

Johnson & Johnson: Strong 1Q Operational Sales Growth Reinforces Our Confidence in 2025 Guidance >JNJ

2025. g. 15. apr. 10:20 UTC

Peļņas

Johnson & Johnson 1Q Sales $21.89B >JNJ

2025. g. 15. apr. 10:20 UTC

Peļņas

Johnson & Johnson: Increasing FY25 Operational Sales Guidance to Reflect Addition of Caplyta Following Completion of Intra-Cellular Therapies Acquisition >JNJ

2025. g. 15. apr. 10:20 UTC

Peļņas

Johnson & Johnson 1Q Worldwide MedTech Sales $8.02B >JNJ

2025. g. 15. apr. 10:20 UTC

Peļņas

Johnson & Johnson 1Q International Sales $9.59B >JNJ

2025. g. 15. apr. 10:20 UTC

Peļņas

Johnson & Johnson 1Q Adj EPS $2.77 >JNJ

2025. g. 15. apr. 10:20 UTC

Peļņas

Johnson & Johnson 1Q Orthopaedics Sales $2.24B >JNJ

2025. g. 15. apr. 10:20 UTC

Peļņas

Johnson & Johnson: MedTech 1Q Operational Sales Growth Driven Primarily by Abiomed and Wound Closure Products, Partially Offset by Spine, Sports & Other >JNJ

2025. g. 15. apr. 10:20 UTC

Peļņas

Johnson & Johnson Still Sees 2025 Adjusted Operational Sales Growth of 2.0%-3.0% >JNJ

2025. g. 15. apr. 10:20 UTC

Peļņas

Johnson & Johnson: Innovative Medicine 1Q Sales Growth Driven in Part by Higher Sales of Darzalex and Spravato, Partially Offset by Falling Sales of Stelara >JNJ

2025. g. 15. apr. 10:20 UTC

Peļņas

Johnson & Johnson 1Q U.S. Sales $12.31B >JNJ

2025. g. 15. apr. 10:20 UTC

Peļņas

Johnson & Johnson 1Q EPS $4.54 >JNJ

Salīdzinājums

Cenas izmaiņa

Johnson and Johnson Prognoze

Cenas mērķis

By TipRanks

8.86% augšup

Prognoze 12 mēnešiem

Vidējais 169.15 USD  8.86%

Augstākais 185 USD

Zemākais 159 USD

Pamatojoties uz 14 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Johnson and Johnson  — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

14 ratings

7

Pirkt

7

Turēt

0

Pārdot

Tehniskais rādītājs

By Trading Central

154.36 / 157.47Atbalsts un pretestība

Īstermiņā

Strong Bullish Evidence

Vidējā termiņā

Bullish Evidence

Ilgtermiņā

Bearish Evidence

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Johnson and Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. Its MedTech segment provides Interventional Solutions, including electrophysiology products to treat heart rhythm disorders; the heart recovery portfolio, which includes technologies to treat severe coronary artery disease requiring high-risk PCI or AMI cardiogenic shock; and neurovascular care that treats hemorrhagic and ischemic stroke. this segment also offers an orthopaedics portfolio that includes products and enabling technologies that support hips, knees, trauma, spine, sports, and other; surgery portfolios comprising advanced and general surgery technologies, as well as solutions for breast aesthetics, ear, nose, and throat procedures; contact lenses under the ACUVUE Brand; and TECNIS intraocular lenses for cataract surgery. It distributes its products to wholesalers, hospitals, and retailers, as well as physicians, nurses, hospitals, eye care professionals, and clinics. The company has a collaboration agreement with Stand Up To Cancer for research testing a combination of teclistamab and daratumumab to treat a rare disease AL amyloidosis. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.